These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 15883908)
1. DNA vaccines forum: how to enhance DNA vaccines safety and potency? Ulmer JB IDrugs; 2005 May; 8(5):357-9. PubMed ID: 15883908 [No Abstract] [Full Text] [Related]
2. The impact of systems approaches on biological problems in drug discovery. Hood L; Perlmutter RM Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453 [No Abstract] [Full Text] [Related]
4. DNA vaccines: ready for prime time? Kutzler MA; Weiner DB Nat Rev Genet; 2008 Oct; 9(10):776-88. PubMed ID: 18781156 [TBL] [Abstract][Full Text] [Related]
5. Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development. Korstanje C Curr Opin Investig Drugs; 2003 May; 4(5):519-21. PubMed ID: 12833643 [No Abstract] [Full Text] [Related]
6. Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans? Frelin L; Brass A; Ahlén G; Brenndörfer ED; Chen M; Sällberg M Drug News Perspect; 2010 Dec; 23(10):647-53. PubMed ID: 21180650 [TBL] [Abstract][Full Text] [Related]
7. Prospects for new TB vaccines: Stop TB Working Group on TB Vaccine Development. Fruth U; Young D Int J Tuberc Lung Dis; 2004 Jan; 8(1):151-5. PubMed ID: 14974759 [TBL] [Abstract][Full Text] [Related]
8. Drug discovery: the leading edge. Chapman T Nature; 2004 Jul; 430(6995):109-15. PubMed ID: 15229608 [No Abstract] [Full Text] [Related]
9. Preclinical and clinical safety studies on DNA vaccines. Schalk JA; Mooi FR; Berbers GA; van Aerts LA; Ovelgönne H; Kimman TG Hum Vaccin; 2006; 2(2):45-53. PubMed ID: 17012886 [TBL] [Abstract][Full Text] [Related]
10. Science, medicine and... the markets. Pawlotsky JM J Hepatol; 2006 Sep; 45(3):341-2. PubMed ID: 16854496 [No Abstract] [Full Text] [Related]
11. Screening for drug discovery: the leading question. Smith A Nature; 2002 Jul; 418(6896):453-9. PubMed ID: 12140563 [No Abstract] [Full Text] [Related]
12. High throughput screening: early successes indicate a promising future. Fox S; Wang H; Sopchak L; Khoury R J Biomol Screen; 2001 Jun; 6(3):137-40. PubMed ID: 11689109 [No Abstract] [Full Text] [Related]
13. A changing drug supply. Nature; 2007 Feb; 445(7127):460. PubMed ID: 17268432 [No Abstract] [Full Text] [Related]
14. A DNA vaccine for the prevention of Ebola virus infection. Dery M; Bausch DG Curr Opin Mol Ther; 2008 Jun; 10(3):285-93. PubMed ID: 18535936 [TBL] [Abstract][Full Text] [Related]
15. The evolution of DNA vaccines. Apostolopoulos V; Plebanski M Curr Opin Mol Ther; 2000 Aug; 2(4):441-7. PubMed ID: 11249775 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Lee LS; Nafziger AN; Bertino JS Clin Pharmacol Ther; 2005 Jul; 78(1):1-6. PubMed ID: 16003286 [No Abstract] [Full Text] [Related]
18. Novel vaccine technology and the future of vaccine science. Lu S Hum Vaccin Immunother; 2014; 10(5):1143-6. PubMed ID: 25290657 [TBL] [Abstract][Full Text] [Related]
19. An update on the state of the art of DNA vaccines. Ulmer JB Curr Opin Drug Discov Devel; 2001 Mar; 4(2):192-7. PubMed ID: 11378958 [TBL] [Abstract][Full Text] [Related]